The Pulse Check

Emyria (ASX: EMD)

Apr 20, 2026

•

11 min read

My Second Armchair Pick: Emyria (ASX: EMD)

Jason Segal

Telix (ASX: TLX)

Apr 17, 2026

•

9 min read

A Beacon of Australian Biotech: The Telix (ASX: TLX) Story

Jason Segal

The Pulse Check

Riding the Peptidal Wave: Biotech Bounce Back

Apr 16, 2026

•

3 min read

Riding the Peptidal Wave: Biotech Bounce Back

Jason Segal

The Pulse Check

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Apr 15, 2026

•

15 min read

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Jason Segal

The Pulse Check

When Shares Become the Vote: The 249D-ilemma

Apr 14, 2026

•

7 min read

When Shares Become the Vote: The 249D-ilemma

Jason Segal

Telix (ASX: TLX)

Telix lights up the deal docket for the ASX biotech sector

Apr 13, 2026

•

8 min read

Telix lights up the deal docket for the ASX biotech sector

Jason Segal

The Pulse Check

While everyone is selling. Big Pharma is buying.

Apr 10, 2026

•

6 min read

While everyone is selling. Big Pharma is buying.

Jason Segal

The Pulse Check

Apr 9, 2026

•

6 min read

Market’s Rocking: A Green Day

Jason Segal

The Pulse Check

Second Mover Advantage: The Neuroscientific Biopharmaceutical (ASX: NSB) Story

Apr 8, 2026

•

15 min read

Second Mover Advantage: The Neuroscientific Biopharmaceutical (ASX: NSB) Story

Jason Segal

The Pulse Check

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

Apr 7, 2026

•

21 min read

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

Jason Segal

The Pulse Check

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

Mar 31, 2026

•

18 min read

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

Jason Segal

The Pulse Check

Mar 30, 2026

•

9 min read

Why Peptides Are Suddenly Everywhere

Jason Segal

Lumos Diagnostics (ASX: LDX)

Crowned then Clipped: When the Raise Gets There Before the Rally

Mar 27, 2026

•

6 min read

Crowned then Clipped: When the Raise Gets There Before the Rally

Jason Segal

Lumos Diagnostics (ASX: LDX)

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Mar 26, 2026

•

9 min read

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Jason Segal

The Pulse Check

Mar 25, 2026

•

5 min read

Why Iran Matters for Biotech Investors

Jason Segal

The Pulse Check

What makes a surgeon use a product? The Orthocell (ASX: OCC) Story.

Mar 24, 2026

•

17 min read

What makes a surgeon use a product? The Orthocell (ASX: OCC) Story.

Jason Segal

Amplia (ASX: ATX)

Mar 23, 2026

•

7 min read

Amplia (ASX: ATX) Delivers: A Result the Biotech Sector Needed

Jason Segal

Amplia (ASX: ATX)

Mar 20, 2026

•

10 min read

Amplia (ASX: ATX) in the Spotlight: Bull, Bear, Base

Jason Segal

The Pulse Check

Don’t sleep on this one: The Avecho (ASX: AVE) Story

Mar 19, 2026

•

15 min read

Don’t sleep on this one: The Avecho (ASX: AVE) Story

Jason Segal

The Pulse Check

Mar 18, 2026

•

3 min read

Flash update on my day trip to Brisbane

Jason Segal

The Pulse Check

Medical Device Playbook: From FDA Clearance to Commercial Success

Mar 17, 2026

•

16 min read

Medical Device Playbook: From FDA Clearance to Commercial Success

Jason Segal

The Pulse Check

First pick flying, plus my plans for the Armchair Portfolio

Mar 16, 2026

•

7 min read

First pick flying, plus my plans for the Armchair Portfolio

Jason Segal

The Pulse Check

My First Armchair Pick: Tetratherix (ASX: TTX)

Mar 16, 2026

•

24 min read

My First Armchair Pick: Tetratherix (ASX: TTX)

Jason Segal

The Pulse Check

Mar 13, 2026

•

4 min read

The Curse of the Friday the 13th

Jason Segal

The Pulse Check

Mar 12, 2026

•

5 min read

A Nervous Wait for the Immutep Results

Jason Segal

The Pulse Check

My Second Armchair Pick: Emyria (ASX: EMD)

A Beacon of Australian Biotech: The Telix (ASX: TLX) Story

Riding the Peptidal Wave: Biotech Bounce Back

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

When Shares Become the Vote: The 249D-ilemma

Telix lights up the deal docket for the ASX biotech sector

While everyone is selling. Big Pharma is buying.

Market’s Rocking: A Green Day

Second Mover Advantage: The Neuroscientific Biopharmaceutical (ASX: NSB) Story

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

Why Peptides Are Suddenly Everywhere

Crowned then Clipped: When the Raise Gets There Before the Rally

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Why Iran Matters for Biotech Investors

What makes a surgeon use a product? The Orthocell (ASX: OCC) Story.

Amplia (ASX: ATX) Delivers: A Result the Biotech Sector Needed

Amplia (ASX: ATX) in the Spotlight: Bull, Bear, Base

Don’t sleep on this one: The Avecho (ASX: AVE) Story

Flash update on my day trip to Brisbane

Medical Device Playbook: From FDA Clearance to Commercial Success

First pick flying, plus my plans for the Armchair Portfolio

My First Armchair Pick: Tetratherix (ASX: TTX)

The Curse of the Friday the 13th

A Nervous Wait for the Immutep Results

The Armchair Analyst